{"id":4294,"date":"2024-02-27T08:18:11","date_gmt":"2024-02-27T16:18:11","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=4294"},"modified":"2024-02-27T08:18:14","modified_gmt":"2024-02-27T16:18:14","slug":"derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/","title":{"rendered":"Derm-Biome Pharmaceuticals \u6e96\u5099\u958b\u59cb DB-007-4 \u7684 IND \u7814\u7a76\uff0c\u9019\u662f\u4e00\u7a2e\u6f5b\u5728\u7684\u540c\u985e\u6700\u4f73\u767c\u708e\u6027\u76ae\u819a\u75c5\u6cbb\u7642\u65b9\u6cd5"},"content":{"rendered":"

\u4e0d\u5217\u985b\u54e5\u502b\u6bd4\u4e9e\u7701\u6eab\u54e5\u83ef\uff0c2024 \u5e742 \u670827 \u65e5\uff08\u74b0\u7403\u901a\u8a0a\u793e\uff09\u2014 Derm-Biome Pharmaceuticals Inc \u662f\u4e00\u5bb6\u7e3d\u90e8\u4f4d\u65bc\u6eab\u54e5\u83ef\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u958b\u767c\u91dd\u5c0d\u708e\u75c7\u6027\u76ae\u819a\u75c5\u548c\u76ae\u819a\u764c\u7684\u65b0\u578b\u5c40\u90e8\u7642\u6cd5\uff0c\u8a72\u516c\u53f8\u5f88\u9ad8\u8208\u5730\u5ba3\u5e03\uff0c\u5b83\u5c07\u5f88\u5feb\u958b\u59cbGLP DB-007-4 \u662f\u4e00\u7a2e\u6f5b\u5728\u7684\u540c\u985e\u6700\u4f73\u4e00\u7dda\u5c40\u90e8\u6cbb\u7642\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u75e4\u7621\u3001\u7570\u4f4d\u6027\u76ae\u819a\u708e (AD) \u548c\u7d05\u6591\u75e4\u7621\u7b49\u767c\u708e\u6027\u76ae\u819a\u75c5\u3002\u6bd2\u7406\u5b78\u7814\u7a76\u662f\u85e5\u7269\u958b\u767c\u7684\u91cd\u8981\u7d44\u6210\u90e8\u5206\uff0c\u56e0\u70ba\u5b83\u5011\u6709\u52a9\u65bc\u5728\u5c0d\u4eba\u9ad4\u9032\u884c\u6e2c\u8a66\u4e4b\u524d\u8a55\u4f30\u5019\u9078\u85e5\u7269\u7684\u6f5b\u5728\u5b89\u5168\u6027\u548c\u6bd2\u6027\u3002<\/p>\n\n\n\n

\u78ba\u5be6\u9700\u8981\u80fd\u5920\u63d0\u4f9b\u9ad8\u6548\u4e14\u9577\u671f\u4f7f\u7528\u4e0d\u826f\u53cd\u61c9\u98a8\u96aa\u4f4e\u7684\u76ae\u819a\u75c5\u85e5\u7269\u3002\u5916\u7528\u985e\u56fa\u9187\u5728\u8a31\u591a\u76ae\u819a\u75c5\u7684\u6cbb\u7642\u4e2d\u767c\u63ee\u91cd\u8981\u4f5c\u7528\uff0c\u4f46\u5b83\u5011\u4e5f\u6703\u5e36\u4f86\u4e0d\u826f\u526f\u4f5c\u7528\u3002\u5c0d\u65bc AD\uff08\u4e00\u7a2e\u5f71\u97ff\u9ad8\u9054 25% \u5b30\u5152\u548c\u5e7c\u5152\u7684\u767c\u708e\u6027\u76ae\u819a\u75c5\uff09\u7b49\u75be\u75c5\uff0c\u9700\u8981\u66f4\u5b89\u5168\u7684\u6cbb\u7642\u9078\u64c7\u3002 DB-007-4 \u662f\u4e00\u7a2e\u5c40\u90e8\u591a\u75be\u75c5\u6cbb\u7642\u85e5\u7269\uff0c\u91dd\u5c0d\u5728\u767c\u708e\u6027\u76ae\u819a\u75c5\u7684\u767c\u5c55\u4e2d\u767c\u63ee\u91cd\u8981\u4f5c\u7528\u7684\u91cd\u8981\u9014\u5f91\uff0c\u540c\u6642\u76ae\u819a\u8010\u53d7\u6027\u826f\u597d\u3002<\/p>\n\n\n\n

Andy Makin, CEO of Andrew Makin Preclinical Consulting ApS, and Derm-Biome dermal and toxicology consultant: \u201cMoving a product into GLP safety studies is an important milestone in the development program, and this is a significant moment for the DB-007-4\u5c08\u6848."<\/p>\n\n\n\n

Derm-Biome \u57f7\u884c\u9577 Gordon Eberwein \u8868\u793a\uff1a\u300c\u6211\u5011\u975e\u5e38\u9ad8\u8208\u80fd\u5920\u5c07\u9019\u7a2e\u6709\u524d\u666f\u7684\u5316\u5408\u7269\u63a8\u5411\u81e8\u5e8a\u8a66\u9a57\u3002\u7814\u7a76\u4e00\u81f4\u8868\u660e\uff0c\u76ee\u524d\u7684\u6cbb\u7642\u65b9\u6848\u7121\u6cd5\u6eff\u8db3\u767c\u708e\u6027\u76ae\u819a\u75c5\u60a3\u8005\u7684\u9700\u6c42\uff0c\u539f\u56e0\u8981\u4e48\u662f\u6548\u679c\u4f4e\u4e0b\uff0c\u8981\u4e48\u662f\u526f\u4f5c\u7528\u3002\u201d<\/p>\n\n\n\n

Derm-Biome \u8a08\u5283\u65bc 2025 \u5e74\u7b2c\u4e8c\u5b63\u63d0\u4ea4 DB-007-4 \u7684\u7814\u7a76\u6027\u65b0\u85e5 (IND) \u7533\u8acb\u3002\u4e00\u65e6\u7372\u5f97\u6279\u51c6\uff0cDerm-Biome \u8a08\u5283\u5728\u5065\u5eb7\u53c3\u8207\u8005\u4e2d\u555f\u52d5 I \u671f\u81e8\u5e8a\u8a66\u9a57\u3002<\/p>\n\n\n\n

\u95dc\u65bc Derm-Biome \u88fd\u85e5\u516c\u53f8<\/strong><\/p>\n\n\n\n

Derm-Biome Pharmaceuticals, Inc. \u662f\u4e00\u5bb6\u81f4\u529b\u65bc\u6539\u5584\u76ae\u819a\u5065\u5eb7\u7684\u81e8\u5e8a\u524d\u751f\u7269\u88fd\u85e5\u516c\u53f8\u3002\u6211\u5011\u6b63\u5728\u958b\u767c\u91dd\u5c0d\u767c\u708e\u6027\u76ae\u819a\u75c5\u548c\u764c\u524d\u76ae\u819a\u75c5\/\u975e\u9ed1\u8272\u7d20\u7624\u76ae\u819a\u764c\u7684\u65b0\u578b\u5c40\u90e8\u7642\u6cd5\uff0c\u9019\u4e9b\u7642\u6cd5\u65e2\u9ad8\u6548\u53c8\u76ae\u819a\u8010\u53d7\u6027\u826f\u597d\u3002<\/p>\n\n\n\n

\u63a5\u89f8
\u6295\u8cc7\u8005\u67e5\u8a62\uff1a
\u6208\u767b\u00b7\u827e\u4f2f\u6eab
geberwein@derm-biome.com<\/a>
https:\/\/derm-biomepharmaceuticals.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

\u4e0d\u5217\u985b\u54e5\u502b\u6bd4\u4e9e\u7701\u6eab\u54e5\u83ef\uff0c2024 \u5e742 \u670827 \u65e5\uff08\u74b0\u7403\u901a\u8a0a\u793e\uff09\u2014 Derm-Biome Pharmaceuticals Inc \u662f\u4e00\u5bb6\u7e3d\u90e8\u4f4d\u65bc\u6eab\u54e5\u83ef\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u958b\u767c\u91dd\u5c0d\u708e\u75c7\u6027\u76ae\u819a\u75c5\u548c\u76ae\u819a\u764c\u7684\u65b0\u578b\u5c40\u90e8\u7642\u6cd5\uff0c\u8a72\u516c\u53f8\u5f88\u9ad8\u8208\u5730\u5ba3\u5e03\uff0c\u5b83\u5c07\u5f88\u5feb\u958b\u59cbGLP DB-007-4 \u7684\u6bd2\u7406\u5b78\u7814\u7a76\u662f\u4e00\u7a2e\u6f5b\u5728\u7684\u540c\u985e\u6700\u4f73\u4e00\u7dda\u5c40\u90e8\u6cbb\u7642\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u75e4\u7621\u3001\u7279\u61c9\u6027\u7b49\u767c\u708e\u6027\u76ae\u819a\u75c5 [\u2026]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"yoast_head":"\nDerm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"zh_HK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-27T16:18:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-27T16:18:14+00:00\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u8a08\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases\",\"datePublished\":\"2024-02-27T16:18:11+00:00\",\"dateModified\":\"2024-02-27T16:18:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"articleSection\":[\"Recent News\"],\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\",\"name\":\"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"datePublished\":\"2024-02-27T16:18:11+00:00\",\"dateModified\":\"2024-02-27T16:18:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#breadcrumb\"},\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"zh-HK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/","og_locale":"zh_HK","og_type":"article","og_title":"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.","og_description":"VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic […]","og_url":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2024-02-27T16:18:11+00:00","article_modified_time":"2024-02-27T16:18:14+00:00","author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"Derm-Biome Admin","\u9810\u8a08\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases","datePublished":"2024-02-27T16:18:11+00:00","dateModified":"2024-02-27T16:18:14+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"articleSection":["Recent News"],"inLanguage":"zh-HK","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/","name":"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"datePublished":"2024-02-27T16:18:11+00:00","dateModified":"2024-02-27T16:18:14+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#breadcrumb"},"inLanguage":"zh-HK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-prepares-to-begin-ind-enabling-studies-for-db-007-4-a-potential-best-in-class-treatment-for-inflammatory-skin-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"zh-HK"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/posts\/4294"}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/comments?post=4294"}],"version-history":[{"count":1,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/posts\/4294\/revisions"}],"predecessor-version":[{"id":4295,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/posts\/4294\/revisions\/4295"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/media?parent=4294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/categories?post=4294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch-s\/wp-json\/wp\/v2\/tags?post=4294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}